Expert Interview
A third look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Ticker(s): SNDX, KURAInstitution: University of Texas Southwestern Medical Center
- Hematopathologist affiliated with UT Southwestern Medical Center
- Research interests include atherosclerosis, thrombosis, vascular biology, lipid metabolism, GVHD, molecular pathogenesis of lymphoma and leukemia, tumor immunology, viral infections and cancergenesis
- Published over 90 peer reviewed papers, 120 abstracts and 11 book chapters
- Manages 45 patients with PNH and has prescribed Epaveli
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
